Pingxiang Jiuyun Body Age Butler Technology Co., Ltd. – Trademark Portfolio
Entity Type: 99
Pingxiang Jiuyun Body Age Butler Technology Co., Ltd. holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include OHLALA. The owner is based in Pingxiang , Jiangxi.
No. 502, Bldg 2, Yidu International Mall
Yingbin Rd, Shangli Tn, Shangli Co
Pingxiang , Jiangxi 337009 , CN
Showing of trademarks Trademarks
Trademark Classifications
Pingxiang Jiuyun Body Age Butler Technology Co., Ltd.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Pingxiang Jiuyun Body Age Butler Technology Co., Ltd. have?
Pingxiang Jiuyun Body Age Butler Technology Co., Ltd. has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.
What trademark classes does Pingxiang Jiuyun Body Age Butler Technology Co., Ltd. file in?
Pingxiang Jiuyun Body Age Butler Technology Co., Ltd. files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Pingxiang Jiuyun Body Age Butler Technology Co., Ltd.'s most well-known trademarks?
Pingxiang Jiuyun Body Age Butler Technology Co., Ltd.'s registered trademark portfolio includes well-known marks such as OHLALA. These are among 1 currently registered trademark in the portfolio.
What is Pingxiang Jiuyun Body Age Butler Technology Co., Ltd.'s trademark registration success rate?
Pingxiang Jiuyun Body Age Butler Technology Co., Ltd. has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.